Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14286049 | 0.88 | MGLL (0.46) | MGLLHRH3MEN1KMT2A | |
| SCHEMBL17754275 | 0.85 | MGLL (0.45) | MGLLCYP4F2CYP4A11HRH3CYP4Z1 | |
| SCHEMBL19504841 | 0.84 | ITGB3 (0.48) | MGLLMEN1KMT2A | |
| SCHEMBL19103219 | 0.81 | MGLL (0.41) | MGLLCYP4F2CYP4A11HRH3CYP4Z1 | |
| SCHEMBL5702491 | 0.81 | MEN1 (0.40) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL13056003 | 0.80 | KMT2A (0.37) | MGLLMEN1KMT2A | |
| SCHEMBL15654561 | 0.80 | RAB9A (0.53) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3660879 | 0.80 | MEN1 (0.39) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4901687 | 0.80 | MGLL (0.43) | MGLLMEN1KMT2A | |
| SCHEMBL22334888 | 0.79 | MGLL (0.48) | MGLLCYP4F2CYP4A11HRH3CYP4Z1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389569-B2 | Polyspirane compounds, application thereof in the treatment of malaria or toxoplasmosis and method for preparing same | UNIVERSITE JOSEPH FOURIER (FR) | 2013-03-05 | — | — | US | disclosed |
| US-8389569-B2 | Polyspirane compounds, application thereof in the treatment of malaria or toxoplasmosis and method for preparing same | UNIVERSITE JOSEPH FOURIER (FR) | 2013-03-05 | — | — | US | disclosed |
| EP-2195323-B1 | Polyspirane compounds, use thereof in the treatment of malaria or toxoplasmosis and method for their preparation | UNIV JOSEPH FOURIER (FR) | 2011-12-28 | — | — | EP | disclosed |
| US-20100298422-A1 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | UNIVERSITE JOSEPH FOURIER (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298422-A1 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | UNIVERSITE JOSEPH FOURIER (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298422-A1 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | FLOT1, PHOSPHO1, GPAA1 | MGLL 1679/4885CYP4F2 2062/4885CYP4A11 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.